

1 **Integrative metabolomics differentiate coronary artery disease, peripheral artery**
2 **disease, and venous thromboembolism risks**

3
4 Jiwoo Lee*^{1,2}, Thomas Gilliland*^{1,2}, Satoshi Koyama¹, Tetsushi Nakao^{1,2,3,4}, Jacqueline
5 Dron^{1,2}, Kim Lannery², Megan Wong², Gina M. Peloso⁵, Whitney Hornsby^{1,2}, Pradeep
6 Natarajan^{1,2,6}

7
8 1 Program in Medical and Population Genetics and the Cardiovascular Disease
9 Initiative, Broad Institute of MIT and Harvard, Cambridge, MA
10 2 Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts
11 General Hospital, Boston, MA
12 3 Brigham and Women's Hospital, Boston, MA
13 4 Dana-Farber Cancer Institute, Boston, MA
14 5 Department of Biostatistics, Boston University School of Public Health, Boston, MA
15 6 Department of Medicine, Harvard Medical School, Boston, MA

16

17 **Abstract**

18 **Rationale**

19 Arterial and venous cardiovascular conditions, such as coronary artery disease (CAD),
20 peripheral artery disease (PAD), and venous thromboembolism (VTE), are genetically
21 correlated. Interrogating distinct and overlapping mechanisms may shed new light on
22 disease mechanisms.

23 **Objective**

24 In this study, we aimed to: identify and compare (1) epidemiologic and (2) causal, genetic
25 relationships between metabolites and CAD, PAD, and VTE.

26 **Methods**

27 We used metabolomic data from 95,402 individuals in the UK Biobank, excluding
28 individuals with prevalent cardiovascular disease. Logistic regression models adjusted for
29 age, sex, genotyping array, first five principal components of ancestry, and statin use
30 estimated the epidemiologic associations of 249 metabolites with incident CAD, PAD, or
31 VTE. Bidirectional two-sample Mendelian randomization (MR) estimated the causal
32 effects between metabolites and cardiovascular phenotypes using genome-wide
33 association summary statistics for metabolites (N = 118,466 from UK Biobank), CAD (N
34 = 184,305 from CARDIoGRAMplusC4D 2015), PAD (N = 243,060 from Million Veterans
35 Project) and VTE (N = 650,119 from Million Veterans Project). Multivariable MR (MVMR)
36 was performed in subsequent analyses.

37 **Results**

38 We found that 194, 111, and 69 metabolites were epidemiologically associated ($P <$
39 0.001) with CAD, PAD, and VTE, respectively. Metabolomic profiles exhibited variable
40 similarity between disease pairs: CAD and PAD (N = 100 shared associations, $R^2 =$

41 0.499), CAD and VTE (N = 68, $R^2 = 0.455$), and PAD and VTE (N = 54, $R^2 = 0.752$). MR
42 revealed 28 metabolites that increased risk for both CAD and PAD and 2 metabolites that
43 increased risk for CAD but decreased risk for VTE. Despite strong epidemiologic overlap,
44 no metabolites had a shared genetic relationship between PAD and VTE. MVMR revealed
45 several metabolites with shared causal effects on CAD and PAD related to cholesterol
46 content within very-low-density lipoprotein particles.

47 **Conclusions**

48 While common arterial and venous conditions are associated with overlapping
49 metabolomic profiles, MR prioritized the role of remnant cholesterol in arterial diseases
50 but not venous thrombosis.

51 **Introduction**

52 Cardiovascular diseases, including coronary artery disease (CAD), peripheral artery
53 disease (PAD), and venous thromboembolism (VTE), remain the leading causes of
54 morbidity and mortality worldwide.¹ Studies suggest mechanistic overlap between CAD
55 and PAD with atherosclerosis as a principal driver of both.^{2,3} In the past decade, genome-
56 wide association studies (GWAS) of CAD, PAD, and VTE have probed the genetic
57 architectures of and between these three phenotypes.^{2,4-6} In addition, CAD, PAD, and
58 VTE often co-occur – upwards of 42% of individuals with CAD also have PAD.⁷
59 Understanding shared and distinct pathways may facilitate therapeutic interventions
60 toward key aspects of disease mechanisms.

61
62 Assessment of the human metabolome is an attractive approach to study mechanistic
63 etiologies, as metabolomics capture exposures from several sources, including genetic,
64 dietary, and lifestyle profiles, that all influence an individual's lifetime risk of various
65 cardiovascular diseases.⁸ Identifying upstream metabolites that affect an individual's risk
66 of CAD, PAD, or VTE and vice versa (i.e., identifying metabolites that are affected by
67 having CAD, PAD, or VTE) are critical to better understand mechanistic etiology. Recent
68 GWAS performed on large-scale metabolomics data⁹ may help to probe the role of the
69 metabolome in explaining the genetic overlap between CAD, PAD, and VTE.⁹
70 Examination of genetic pleiotropy offers a new opportunity to shed new light on disease
71 pathogenesis.¹⁰

72
73 Mendelian randomization (MR) can estimate causal effects between metabolites and
74 CAD, PAD, and VTE. MR is a causal inference approach that uses genetic instruments
75 as instrumental variables to prioritize potentially causal relationships between
76 exposures and outcomes, with corresponding lowering risks of confounding and reverse
77 causation.¹¹ MR is particularly well-suited for estimating the causal effects of
78 metabolites, especially given their strong heritability¹² and recent in-depth molecular
79 profiling of metabolites in the UK Biobank.^{13,14} Given widespread correlation of
80 metabolites, we leverage methodologic advances accounting for horizontal pleiotropic
81 effects and potential reverse causation.

82
83 In this study, we aimed to: (1) identify and compare associations of metabolites with
84 CAD, PAD, and VTE and (2) identify and compare causal effects of metabolites with
85 CAD, PAD, and VTE. Specifically, we performed association analyses and bidirectional
86 two-sample MR analyses in the UK Biobank with 95,402 individuals with in-depth
87 molecular profiling of metabolites and non-overlapping genetic data for the
88 cardiovascular outcomes from large-scale GWAS consortia.

89
90

91 **Methods**

92 **Study cohort**

93 The UK Biobank study cohort has been described previously.¹⁴ Briefly, the UK Biobank
94 is a large population-based prospective study that contains genotype and phenotype data
95 from 502,639 individuals living in the United Kingdom and recruited between 2006 and
96 2010.¹⁴ Individuals who were closely related, withdrew consent, or had prevalent CAD,
97 PAD, or VTE at baseline were excluded. CAD, PAD, and VTE were defined by the
98 International Classification of Diseases (ICD) system, specifically ICD-10 codes
99 (**Supplementary Table 1**). In CARDIoGRAMplusC4D 2015, CAD cases were similarly
100 defined by an inclusive CAD diagnosis (e.g., myocardial infarction, acute coronary
101 syndrome, chronic stable angina, or coronary stenosis > 50%).¹⁵ In the Million Veterans
102 Program, PAD and VTE were similarly defined by ICD-9, ICD-10, and Current Procedural
103 Terminology (CPT) codes (**Supplementary Table 1**).^{2,6}

104
105 A random subset of non-fasting baseline plasma samples from 118,466 individuals and
106 1,298 repeat visit samples were measured for 249 metabolomic biomarkers using a high-
107 throughput nuclear magnetic resonance (NMR) metabolomic biomarker profiling platform
108 developed by Nightingale Health (Helsinki, Finland) in the UK Biobank.⁹ The metabolites
109 span multiple metabolic pathways, including lipoprotein lipids in 14 subclasses, fatty acids
110 and fatty acid compositions, as well as various low-molecular weight metabolites, such
111 as amino acids, ketone bodies, and glycolysis metabolites, all quantified in molar
112 concentration units.⁹ A total of 95,402 individuals were included in this study.

113
114 **Genetic correlation between cardiovascular phenotypes**
115 After variant filtering (e.g., INFO > 0.9 and minor allele frequency (MAF) > 0.01), linkage
116 disequilibrium score regression (LDSC) with default parameters were used to calculate
117 the genetic correlation between CAD and PAD, CAD and VTE, and PAD and VTE using
118 HapMap3 single nucleotide polymorphisms (SNPs) in the 1000 Genomes Project
119 European reference panel.¹⁶ Summary statistics for CAD were obtained from
120 CARDIoGRAMplusC4D 2015 that filtered out individuals from the UK Biobank,¹⁵ and
121 summary statistics for PAD and VTE were obtained from the Million Veterans Program.^{2,6}

122
123 **Association analysis of metabolites with cardiovascular phenotypes**
124 To estimate epidemiologic associations of 249 metabolites with CAD, PAD, and VTE, we
125 constructed logistic models regressing metabolite measurements on CAD, PAD, and VTE
126 coded as a binary indicator for incident event, with covariates including age, sex,
127 genotyping array, five genetic principal components, and self-reported statin use. A
128 correction factor of 0.5 multiplied by the minimum non-zero value of each metabolite was
129 applied prior to log transformation of metabolite values. Transformed metabolite values
130 were scaled with a mean of 0 and a standard deviation of 1. Effect sizes and standard

131 errors were reported, and alpha was defined as $0.05 / 41 = 0.001$. Bonferroni correction
132 for multiple-hypothesis testing is too strict given the high degree of correlation of the 249
133 metabolites, as previously described.¹⁷ Consistent with prior studies to minimize both type
134 I and type II errors, we adjusted for the number of principal components ($N = 41$) that
135 explain 99% of the variance in the data (e.g., $0.05 / 41 = 0.001$).¹⁷ To estimate the
136 correlations of associations between CAD, PAD, and VTE, we calculated the Pearson
137 correlation coefficients of z-scores from logistic regression as a measure of metabolomic
138 profile overlap.

139

140 **Mendelian randomization of metabolites and cardiovascular phenotypes**

141 Mendelian randomization (MR) is a method that uses genetic variants as instrumental
142 variables to prioritize causal relationships between exposures and outcomes.¹¹ MR relies
143 on several assumptions: (1) genetic instruments must be robustly associated with the
144 exposure, (2) genetic instruments must not be associated with confounders, and (3) genetic instruments must not influence the outcome except
145 through the exposure.¹¹ Two-sample MR utilizes GWAS summary statistics in non-
146 overlapping cohorts for exposures and outcomes.¹⁸ We used two non-overlapping
147 cohorts for metabolites and cardiovascular outcomes. Summary statistics for metabolites
148 were obtained from publicly available GWAS summary statistics from the OpenGWAS
149 platform (<https://gwas.mrcieu.ac.uk/>), which contained 249 metabolites from the UK
150 Biobank measured by Nightingale Health (**Supplementary Table 2**).¹⁹ Summary
151 statistics were not adjusted for statin use. Summary statistics for CAD were obtained from
152 CARDIoGRAMplusC4D 2015,¹⁵ and summary statistics for PAD and VTE were obtained
153 from the Million Veteran Program.^{2,6}

154

155 We performed bidirectional, two-sample MR using the TwoSampleMR^{20,21} R package to
156 estimate the causal effects between metabolites and CAD, PAD, and VTE. All analyses
157 were consistent with current recommendations for MR.²² We performed linkage
158 disequilibrium (LD) clumping with a window > 10000 kb and an $R^2 > 0.001$. Genetic
159 instruments were defined to be genetic variants that were significant at the genome-wide
160 significance level after LD clumping ($P < 5 \times 10^{-8}$). A median of 66 SNPs were used as the
161 instrumental variables for the metabolites ($SD = 19.9$, minimum N SNPs = 7, maximum N
162 SNPs = 112), and instrumental variables were robust, with all F-statistics greater than 50.
163 We utilized the inverse variance weighted method, which regresses associations between
164 genetic instruments and outcomes upon associations between genetic instruments and
165 exposures.²³

166

167 In subsequent sensitivity analyses, we utilized the MR Egger, weighted median, simple
168 mode, and weighted mode methods as well, as such methods may be more robust to
169 pleiotropy. We also conducted tests for heterogeneity and horizontal pleiotropy. In MR, a
170

171 test for heterogeneity assesses the compatibility of instrumental variable estimates based
172 on individual genetic variants and is calculated using Cochran's Q test on the causal
173 estimates from individual genetic variants.²⁴ We considered $P > 0.05$ to indicate no
174 statistical evidence of heterogeneity. A test for horizontal pleiotropy is calculated using
175 the MR Egger regression method, as the slope coefficient estimates the causal effect that
176 is consistently asymptotically even if individual genetic variants have pleiotropic effects.²⁴
177 We considered $P > 0.05$ to indicate no statistical evidence of horizontal pleiotropy.

178
179 In the first analysis, in which metabolites were exposures and CAD, PAD, and VTE were
180 outcomes, genetic instruments were clumped and selected based on the above criteria
181 (e.g., $P < 5 \times 10^{-8}$ for metabolite association from GWAS). In the second analysis, in which
182 metabolites were outcomes and CAD, PAD, and VTE were exposures, genetic
183 instruments were clumped and selected based on the above criteria (e.g., $P < 5 \times 10^{-8}$ for
184 CAD, PAD, or VTE association from GWAS). To estimate the correlations of causal
185 effects between CAD, PAD, and VTE, we calculated the Pearson correlation coefficients
186 of betas from MR as a measure of metabolomic profile overlap.

187
188 Given the high degree of correlation among metabolites, we also performed multivariable
189 Mendelian randomization (MVMR), which uses genetic variants for two or more
190 exposures to simultaneously estimate the causal effect of each exposure on the outcome,
191 controlling for the effect of other included exposures. MVMR requires the same
192 assumptions as univariable MR, but the genetic instruments must be associated with the
193 set of exposures rather than the single exposure, but it is not necessary for each genetic
194 instrument to be significantly associated with every exposure.²⁵ In other words,
195 instruments are selected for each exposure and then all exposures for such instruments
196 are regressed against the outcome together, weighting for the inverse variance of the
197 outcome. MVMR was performed using the set of metabolites that were identified to have
198 causal effects in the first analysis, such that the exposures included the set of significant
199 metabolites and the outcomes included CAD, PAD, and VTE separately, in order to
200 identify metabolites that had both strong and independent causal effects.

201
202 All analyses were performed using R version 4.1 and all plots were generated using the
203 R package "ggplot2". A heatmap was generated using the R package "gplots".

204 205 **Results**

206 We estimated associations of 249 metabolites with CAD, PAD, and VTE in 95,402
207 individuals in the UK Biobank, which included 3,209 CAD cases, 846 PAD cases, and
208 1,474 VTE cases (**Figure 1**). The study cohort of 95,402 comprised of 233,202 (55%)
209 females with a mean (standard deviation) age of 56.3 (8.0) years, and 57,948 (14%)
210 individuals prescribed statins (**Table 1**). The GWAS summary statistics for CAD included

211 60,801 cases and 123,504 controls across 48 non-overlapping studies;¹⁵ for PAD
212 included 31,307 cases and 211,753 controls from the Million Veterans Program;² and for
213 VTE included 26,066 cases and 624,053 controls from the Million Veterans Program.⁶
214 We calculated the genetic correlations across the three sets of summary statistics. CAD
215 and PAD shared the highest genetic correlation ($R_g = 0.6615$, $SE = 0.044$, $P = 4.51 \times 10^{-51}$),
216 followed by PAD and VTE ($R_g = 0.2463$, $SE = 0.053$, $P = 3.28 \times 10^{-6}$) and CAD and
217 VTE ($R_g = 0.1300$, $SE = 0.0480$, $P = 6.80 \times 10^{-3}$).

218 219 **Epidemiologic associations reveal overlap of metabolites between cardiovascular** 220 **phenotypes**

221 We found 194, 111, and 69 metabolites epidemiologically associated with CAD, PAD,
222 and VTE, respectively (**Figure 2, Supplementary Table 3**). Phospholipids / total lipids in
223 large VLDL (odds ratio (OR) = 1.62, 95% CI = [1.39, 1.89], $P = 5.04 \times 10^{-10}$) and
224 apolipoprotein B / apolipoprotein A1 (OR = 1.43, 95% CI = [1.37, 1.49], $PS = 7.29 \times 10^{-72}$)
225 were among the top metabolites associated with increased CAD risk, while cholesteryl
226 esters in high-density lipoprotein (HDL) were associated with decreased CAD risk (OR =
227 0.73, 95% CI = [0.70, 0.75], $P = 1.82 \times 10^{-58}$). Glycoprotein acetyls were associated with
228 increased PAD risk (OR = 1.40, 95% CI = [1.31, 1.50], $P = 7.57 \times 10^{-24}$) and degree of
229 unsaturation of all fatty acids was associated with decreased PAD risk (OR = 0.72, 95%
230 CI = [0.68, 0.77], $P = 1.47 \times 10^{-22}$). Phospholipids / total lipids in medium HDL was
231 associated with increased VTE risk (OR = 1.21, 95% CI = [1.14, 1.29], $P = 2.29 \times 10^{-9}$)
232 while albumin was associated with decreased VTE risk (OR = 0.80, 95% CI = [0.77, 0.84],
233 $P = 1.11 \times 10^{-18}$).

234
235 Next, we estimated the overlap of metabolomic associations across CAD, PAD, and VTE.
236 There were 52 metabolites that had significant ($P < 0.001$) associations with all three
237 cardiovascular phenotypes, of which 50 metabolites had the same direction of effect and
238 2 metabolites had the opposite direction of effect of CAD compared to PAD and VTE.
239 CAD and PAD shared 48 significant metabolites (30 concordant, 18 discordant), CAD
240 and VTE shared 16 metabolites (16 concordant, 0 discordant), and PAD and VTE shared
241 2 metabolites (2 concordant, 0 discordant) (**Figure 3**). Epidemiologic metabolomic
242 profiles were most similar between PAD and VTE ($R^2 = 0.75$, $P = 8.43 \times 10^{-775}$), followed
243 by CAD and PAD ($R^2 = 0.50$, $P = 5.71 \times 10^{-395}$) and CAD and VTE ($R^2 = 0.46$, $P = 2.14 \times 10^{-345}$).
244 In other words, while CAD and PAD shared the highest genetic correlation, PAD and
245 VTE shared the highest similarity of metabolomic associations (**Supplementary Figure**
246 **1**).

247 248 **Estimation of causal effects of metabolites on cardiovascular phenotypes reveal** 249 **overlap between coronary artery disease and peripheral artery disease**

250 Then, we used bidirectional MR to identify potential causal relationships between
251 metabolites and CAD, PAD, and VTE (**Figure 4, Supplementary Figure 2**). We found
252 82 metabolites that increased and 5 that decreased risk for CAD, 25 metabolites that
253 increased and 11 that decreased risk for PAD, and 2 metabolites that decreased risk for
254 VTE ($P < 0.001$). Many of the HDL traits were found to have causal effects on PAD while
255 many of the IDL traits, and larger-sized lipid traits, were found to have causal effects on
256 CAD. Most VLDL and LDL traits were shared by both CAD and PAD. We also performed
257 sensitivity analyses using the MR Egger, weighted median, simple mode, and weighted
258 mode methods (**Supplementary Tables 4-9**), as well as testing for heterogeneity
259 (**Supplementary Table 10**) and horizontal pleiotropy (**Supplementary Tables 11**) to
260 assess the robustness of our results and instrumental variables. Most metabolites
261 showed no statistical evidence ($P > 0.05$) for horizontal pleiotropy in their causal effects
262 on CAD ($N = 175$ metabolites without horizontal pleiotropy), PAD ($N = 200$), and VTE (N
263 $= 246$).

264
265 Conversely, while we found that CAD increased 14 metabolites and decreased 6
266 metabolites, we found no metabolites affected by PAD or VTE. Interestingly, 5 of the 14
267 metabolites had bidirectional, increased causality with CAD (e.g., the metabolite
268 increased risk of CAD and CAD also increased levels of the metabolite) and were all
269 involved in cholesterol concentrations in large VLDL and extremely large VLDL
270 (**Supplementary Figure 3**). In addition, 2 of the 6 metabolites had bidirectional,
271 decreased causality with CAD (e.g., the metabolite decreased risk of CAD and CAD also
272 decreased levels of the metabolite) and were all involved in triglyceride concentrations in
273 large VLDL and very large VLDL (**Supplementary Figure 3**). For the 7 metabolites with
274 bidirectional, causal effects with CAD, there were only one overlap in the variants driving
275 the causal effect of the metabolite on CAD and the variants driving the causal effect of
276 CAD on the metabolite: rs2519093 and rs7528419. The majority of genetic variants only
277 had a causal effect on the metabolite or CAD in a single direction.

278
279 Causal metabolomic profiles were most similar between CAD and PAD ($R^2 = 0.43$, $P =$
280 4.67×10^{-156}), followed by PAD and VTE ($R^2 = 0.06$, $P = 3.55 \times 10^{-17}$) and CAD and VTE (R^2
281 $= 0.03$, $P = 9.38 \times 10^{-11}$). MR revealed 28 metabolites that increased risk for both CAD and
282 PAD and 2 metabolites that increased risk for CAD but decreased risk for VTE (i.e.,
283 triglycerides in low-density lipoprotein (LDL), triglycerides in medium LDL). (**Figure 5**).
284 There were no metabolites with shared causal relationships between PAD and VTE. Of
285 the 28 metabolites shared between CAD and PAD, 64.3% ($N = 18$) were VLDL, 21.4%
286 ($N = 6$) were LDL, 7.1% ($N = 2$) were HDL, 3.6% ($N = 1$) were IDL, and 3.6% ($N = 1$) were
287 apolipoprotein traits. Many of the triglyceride-containing lipid traits that were
288 epidemiologically associated with CAD and PAD did not maintain causal effects; rather,
289 the 28 metabolites shared between CAD and PAD included many cholesterol-containing

290 lipid traits but no triglyceride-containing lipid traits. Taken together with the epidemiologic
291 association results, this suggests that while PAD and VTE maintain similar metabolomic
292 associations, these effects are not robust under a causal framework such that CAD and
293 PAD retain more similar causal metabolomic profiles (**Supplementary Figure 1**).
294 Notably, many of the epidemiologic associations that were not maintained upon
295 interrogation via MR included non-lipid traits, such as glucose and other amino acids.

296
297 Given the high degree of correlation of metabolites among each other, we used MVMR
298 to identify metabolites that had causal effects on CAD, PAD, and VTE independent of
299 other metabolites (**Supplementary Tables 9-11**). In three models including the 87, 36,
300 and 2 metabolites with causal effects on CAD, PAD, and VTE as exposures, we identified
301 7 metabolites with marginal ($P < 0.05$) independent causal effects on CAD (i.e.,
302 cholesteryl esters in VLDL, total lipids in small VLDL, concentration of medium VLDL
303 particles, total lipids in lipoprotein particles, total lipids in LDL, triglycerides to total lipids
304 ratio in large HDL, and total cholesterol minus HDL-C) and 5 on PAD (i.e., cholesteryl
305 esters in small VLDL, phospholipids in small VLDL, free cholesterol in small VLDL,
306 cholesterol in small VLDL, and apolipoprotein B / apolipoprotein A1). We did not identify
307 any metabolites with independent causal effects on VTE. In a separate model excluding
308 the 7 metabolites that had bidirectional, causal effects with CAD, we identified 8
309 metabolites with marginal ($P < 0.05$) independent causal effects on CAD (i.e., total lipids
310 in LDL, cholesterol in IDL, cholesteryl esters in medium LDL, apolipoprotein B, free
311 cholesterol in medium LDL, total lipids in lipoprotein particles, concentration of medium
312 VLDL particles, and total lipids in IDL). There were three metabolites with marginal
313 independent causal effects in both models including the primary model including all 87
314 metabolites and the secondary model excluding the 7 metabolites that had bidirectional,
315 causal effects on CAD (i.e., total lipids in lipoprotein particles, total lipids in LDL,
316 concentration of medium VLDL particles).

317
318 **Discussion**
319 Here, we performed hypothesis-free association analyses and MR analyses to evaluate
320 the metabolomic profiles of CAD, PAD, and VTE covering 249 metabolites in 95,402
321 individuals in the UK Biobank. This allowed us to compare metabolomic profiles between
322 these three cardiovascular phenotypes to provide insight into potential similarities and
323 differences in their metabolomic etiologies.

324
325 First, we found overlap in associated metabolomic profiles of CAD, PAD, and VTE via
326 association analyses. We identified 194, 111, and 69 metabolites that were associated
327 with CAD, PAD, and VTE, respectively, that were also consistent with well-established
328 biology, such as the association between apolipoprotein B and apolipoprotein A1 with
329 CAD. We compared the associated metabolites across CAD, PAD, and VTE and found

330 that CAD and PAD shared 48 metabolites, CAD and VTE shared 16 metabolites, and
331 PAD and VTE shared 2 metabolites - there were 52 metabolites shared by all three
332 cardiovascular phenotypes. There was a high degree of similarity in metabolomic
333 associations between PAD and VTE compared to CAD and VTE. Identification of
334 epidemiologic associations provided a background comparison for subsequent estimation
335 of causal effects.

336
337 Second, we found that overlap in the causal metabolic profiles of CAD and PAD, but not
338 VTE, via MR analyses. This is consistent with the high co-occurrence of CAD and PAD,
339 as well as the genetic correlation, reported by previous studies.^{2,4-7} We identified several
340 upstream metabolites that affected an individual's risk of CAD (N = 87), PAD (N = 36),
341 and VTE (N = 2). Specifically, 28 metabolites increased the risk for both CAD and PAD
342 and 2 metabolites had opposite causal effects in CAD and VTE. Of the 28 metabolites
343 many were VLDL traits, and indeed, VLDL pathways have been implicated in both CAD²⁶
344 and PAD.²⁷ VLDL is a precursor to LDL and is considered to be a marker of atherogenic
345 lipoprotein remnants.²⁸ Given that both CAD and PAD are characterized by the buildup
346 of plaque in coronary or peripheral arteries, it is possible that VLDL, specifically the
347 smaller VLDL particles that are closer in metabolomic identity to LDL, contributes to the
348 development of atherosclerotic lesions in both arterial locations. The convergence of
349 VLDL cholesterol concentrations between CAD and PAD metabolomic profiles
350 strengthens this shared disease mechanism. This result supports the prioritization of
351 atherogenic lipoprotein remnants as a high-yield therapeutic target for both CAD and PAD
352 due to overlaps in lipid-related etiology. Furthermore, no triglyceride-containing lipid traits
353 were shared between CAD and PAD, while many cholesterol-containing lipid traits were
354 shared. Given that previous studies have suggested that triglycerides are not atherogenic,
355 the overrepresentation of cholesterol-containing lipid traits further supports the role of
356 lipid-related etiology underlying the atherosclerotic mechanisms of both CAD and PAD,
357 specifically the cholesterol content of VLDL particles.^{29,30}

358
359 Thus, while the association analyses showed a high degree of metabolomic associations
360 between PAD and VTE, causal effects of metabolites were shared between CAD and
361 PAD to a greater degree than CAD and VTE. Lipid traits may not be as strongly involved
362 in thrombus formation as it is in plaque formation, as VTE had few lipid traits with causal
363 effects with CAD or PAD. Previous studies have highlighted carnitine species, glucose,
364 phenylalanine, among other metabolites, but not lipid-related metabolites, as possibly
365 related to VTE.³¹ We similarly found that several epidemiologic associations identified via
366 association analyses, such as glucose and other amino acids, did not maintain robust
367 causal effects upon interrogation via MR.

368

369 Third, we found that CAD may amplify the effects of some metabolites, particularly
370 cholesterol and triglycerides within VLDL. Using bidirectional MR, we identified 20
371 downstream metabolites that had levels affected by CAD, but not PAD or VTE. Most of
372 the 20 metabolites were involved in VLDL and LDL particles, and those that had positive
373 bidirectional effects with CAD included cholesterol concentrations and those that had
374 negative bidirectional effects with CAD included triglyceride concentrations. Regarding
375 VTE, the null effects of metabolites on VTE and vice versa in a bidirectional MR analysis
376 was previously reported for LDL, HDL, and TGs.³² Regarding CAD, this bidirectional effect
377 may suggest that atherosclerosis itself may influence lipid metabolism. Tomas et al. found
378 distinct metabolomic profiles in high-risk and stable atherosclerotic plaques consistent
379 with different transcription levels of metabolic enzymes, suggesting that atherosclerosis
380 itself may affect metabolite levels.³³ Further functional studies are needed to evaluate this
381 bidirectional effect.

382
383 The limitations of this study should be considered. First, the power and precision of MR
384 is limited to the strength and availability of instrumental variables, such as for VTE. As
385 more powerful GWAS are performed that produce more, high-quality instrumental
386 variables, the MR results will necessarily become stronger and more robust.
387 Nevertheless, the power and precision of MR is driven by the heritability of metabolites,
388 due to its dependence on genetic instruments, and some truly causal metabolites may
389 have low power. Second, because the MR analyses use genetic instruments as
390 instrumental variables, they capture estimates based on lifelong genetic exposures
391 without consideration for acute or temporary effects. For example, MR does not account
392 for the effects of initiating statin therapy in older ages. Third, MR infers causality based
393 on observational data, therefore provides causal estimates without definitively
394 establishing causality. Fourth, the UK Biobank is predominantly composed of individuals
395 from European ancestry, so the generalizability of our findings to other ancestry groups
396 may be limited.

397
398 Taken together, we found that metabolomic profiles identified via MR are shared across
399 CAD and PAD, but not VTE, suggesting similarities in plaque formation over thrombus
400 formation with respect to blood-based metabolomics. In addition, this suggests that the
401 similarities in plaque formation (e.g., CAD and PAD) outweigh similarities in location (e.g.,
402 coronary arteries for CAD, and peripheral beds for PAD and VTE). Atherosclerotic
403 mechanisms, such as VLDL pathways, may be implicated in plaque formation, but not
404 thrombus formation.

405 **Acknowledgements**

406
407 Dr. Gilliland was partially supported by the National Heart, Lung, and Blood Institute T32
408 grant 5T32HL125232. Dr. Nakao is supported by the Japan Society for the Promotion of
409 Science Overseas Fellowship. Dr. Peloso is support by grants from the National Heart
410 Lung and Blood Institute (R01HL142711, R01HL127564). Dr. Natarajan is supported by
411 grants from the National Heart Lung and Blood Institute (R01HL142711, R01HL127564,
412 R01HL148050, R01HL151283, R01HL148565, R01HL135242, R01HL151152),
413 National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125782),
414 Fondation Leducq (TNE-18CVD04), and Massachusetts General Hospital (Paul and
415 Phyllis Fireman Endowed Chair in Vascular Medicine).

416

417 **Ethics Declarations**

418
419 P.N. reports research grants from Allelica, Apple, Amgen, Boston Scientific, Genentech
420 / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life
421 Sciences, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, and
422 Novartis, scientific advisory board membership of Esperion Therapeutics, Preciseli, and
423 TenSixteen Bio, scientific co-founder of TenSixteen Bio, equity in Preciseli and
424 TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to
425 the present work.

Figures

Figure 1. Study schematic. (A) Epidemiological association analysis was performed using individual-level data from the UK Biobank, regressing incident coronary artery disease (CAD)/peripheral artery disease (PAD)/venous thromboembolism (VTE) events on metabolite levels. (B) Bidirectional Mendelian randomization analysis was performed using metabolite summary statistics from the UK Biobank as exposures and CAD/PAD/VTE summary statistics from either CARDIoGRAMplusC4D 2015 or Million Veterans Program (MVP) as outcomes, and (C) vice versa. (D) Taking only the metabolite with significant causal effects from (B), multivariable Mendelian randomization analysis was performed using metabolite summary statistics from the UK Biobank as exposures and CAD/PAD/VTE summary statistics from either CARDIoGRAMplusC4D 2015 or MVP as outcomes.




Figure 2. Epidemiological associations between metabolites and incident cardiovascular outcomes. Associations were estimated using logistic regression on 95,402 individuals in the UK Biobank and 7 classes of metabolites: VLDL = very low-density lipoprotein, FA = fatty acid, HDL = high-density lipoprotein, IDL = intermediate-density lipoprotein, LDL = low-density lipoprotein, M = miscellaneous, NL = non-lipid metabolite, and OL = other lipid metabolite. Bars oriented upwards indicate a positive association while those oriented inwards indicate a negative association. Error bars represent 95% confidence intervals. Transparent bars represent associations that were not significant based on a multiple testing correction of $P < 0.05 / 41$. Coronary artery disease (CAD) was associated with 194 metabolites. Peripheral artery disease (PAD) was associated with 111 metabolites. Venous thromboembolism (VTE) was associated with 69 metabolites.




Figure 3. Venn diagram of metabolites with shared significant associations between coronary artery disease (CAD), peripheral artery disease (PAD), and venous thromboembolism (VTE) estimated using logistic regression. Associations were estimated using logistic regression on 95,402 individuals in the UK Biobank. Metabolites that were associated with more than one cardiovascular phenotype but demonstrated an opposite direction of effect were indicated with white asterisks.




Figure 4. Forest plots of estimated causal effects of genetically-determined metabolites on cardiovascular outcomes estimated using bidirectional Mendelian randomization. Bidirectional, two-sample inverse variance weighted Mendelian randomization using summary statistics from the UK Biobank and CARDIoGRAMplusC4D 2015 or Million Veterans Program (MVP) was performed to estimate causal effects of metabolites on coronary artery disease (CAD), peripheral artery disease (PAD), and venous thromboembolism (VTE). Bars are effect estimates from Mendelian randomization. Error bars represent 95% confidence intervals. Transparent bars represent associations that were not significant based on a multiple testing correction of $P < 0.05 / 41$. There were 87, 36, and 2 metabolites with a causal effect on CAD, PAD, and VTE, respectively.





Figure 5. Venn diagram of metabolites with shared causal effects between coronary artery disease (CAD), peripheral artery disease (PAD), and venous thromboembolism (VTE) estimated using bidirectional Mendelian randomization. Bidirectional, two-sample inverse variance weighted Mendelian randomization using summary statistics from the UK Biobank and CARDIoGRAMplusC4D 2015 or Million Veterans Program (MVP) was performed to estimate causal effects of metabolites on CAD, PAD, and VTE. Metabolites that had causal effects on more than one cardiovascular phenotype but demonstrated an opposite direction of effect were indicated with white asterisks.




Tables

Table 1. Baseline characteristics of analyzed UK Biobank participants. Individuals with prevalent CAD, PAD, or VTE were excluded, leaving 3,209, 846, 1,474 incident coronary artery disease (CAD), peripheral artery disease (PAD), and venous thromboembolism (VTE) cases. The baseline characteristics are reported below.


N	95,402
Age (SD)	56.3 (8.0)
N Female (%)	52,065 (54.6%)
N European (%)	89,847 (94.2%)
N Hypertension (%)	26,507 (27.8%)
N Diabetes (%)	1,974 (2.1%)
N Current Smoker (%)	9,754 (10.2%)
N Statin Users	13,204 (13.8%)
Total cholesterol, mg/dL (SD)	221.5 (43.4)
Low-density lipoprotein cholesterol, mg/dL (SD)	138.7 (33.2)
High-density lipoprotein cholesterol, mg/dL (SD)	56.3 (14.7)
Triglycerides, mg/dL (SD)	153.2 (89.1)
N Incident CAD (%)	3,209 (3.36%)
N Incident PAD (%)	846 (0.887%)
N Incident VTE (%)	1,474 (1.55%)


Supplement

Supplementary Figure 1. Heatmap summarizing correlation of (A) epidemiologic associations and (B) causal effects of metabolites on cardiovascular phenotypes. (A) Epidemiologic associations were estimated using logistic regression on 95,402 individuals in the UK Biobank. Epidemiologic metabolomic profiles were most similar between PAD and VTE ($R^2 = 0.75$, $P = 8.43 \times 10^{-775}$), followed by CAD and PAD ($R^2 = 0.50$, $P = 5.71 \times 10^{-395}$) and CAD and VTE ($R^2 = 0.46$, $P = 2.14 \times 10^{-345}$). (B) Causal effects were estimated using Mendelian randomization using summary statistics from the UK Biobank and CARDIoGRAMplusC4D 2015 or Million Veterans Program (MVP). Causal metabolomic profiles were most similar between CAD and PAD ($R^2 = 0.43$, $P = 4.67 \times 10^{-156}$), followed by PAD and VTE ($R^2 = 0.06$, $P = 3.55 \times 10^{-17}$) and CAD and VTE ($R^2 = 0.03$, $P = 9.38 \times 10^{-11}$).




Correlation of Epidemiologic Associations of Metabolites with Cardiovascular Phenotypes







Correlation of Causal Effects of Metabolites on Cardiovascular Phenotypes



Supplementary Figure 2. Forest plots of estimated causal effects of cardiovascular outcomes on metabolites estimated using bidirectional Mendelian randomization. Bidirectional, two-sample inverse variance weighted Mendelian randomization using summary statistics from the UK Biobank and CARDIoGRAMplusC4D 2015 or Million Veterans Program (MVP) was performed to estimate causal effects of coronary artery disease (CAD), peripheral artery disease (PAD), and venous thromboembolism (VTE) on metabolites. Bars are effect estimates from Mendelian randomization. Error bars represent 95% confidence intervals. Transparent bars represent associations that were not significant based on a multiple testing correction of $P < 0.05 / 41$. Only 20 metabolites were causally affected by a cardiovascular outcome, CAD.



Supplementary Figure 3. Forest plots of estimated causal effects of metabolites on coronary artery disease and vice versa estimated using bidirectional Mendelian randomization. Bidirectional, two-sample inverse variance weighted Mendelian randomization using summary statistics from the UK Biobank and CARDIoGRAMplusC4D 2015 was performed to estimate causal effects of metabolites on coronary artery disease (CAD) and vice versa. Bars are effect estimates from Mendelian randomization. Error bars represent 95% confidence intervals. Of 7 metabolites with bidirectional causal effects, 2 metabolites decreased risk of CAD and also had levels affected by CAD downstream (e.g., having CAD decreased levels of the metabolite) and 5 metabolites increased risk of CAD and also had levels affected by CAD downstream (e.g., having CAD increased levels of the metabolite).



Supplementary Table 1. Phenotype definitions for coronary artery disease (CAD) in CARDIoGRAMplusC4D 2015, peripheral artery disease (PAD) in Million Veterans Program (MVP), and venous thromboembolism (VTE) in MVP.

Supplementary Table 2. Summary of instrumental variables for metabolites in the UK Biobank.

Supplementary Table 3 Table of association analysis estimates between metabolites and coronary artery disease (CAD), peripheral artery disease (PAD), and venous thromboembolism (VTE). Associations were estimated using logistic regression on 95,402 individuals in the UK Biobank.

Supplementary Table 4. Table of bidirectional, two-sample Mendelian randomization using the MR Egger, weighted median, inverse variance weighted, simple mode, and weighted mode method estimates using metabolite summary statistics from the UK Biobank as exposures and coronary artery disease (CAD) summary statistics from CARDIoGRAMplusC4D 2015 as the outcome.

Supplementary Table 5. Table of bidirectional, two-sample Mendelian randomization using the MR Egger, weighted median, inverse variance weighted, simple mode, and weighted mode method estimates using metabolite summary statistics from the UK Biobank as outcomes and coronary artery disease (CAD) summary statistics from CARDIoGRAMplusC4D 2015 as the exposure.

Supplementary Table 6. Table of bidirectional, two-sample Mendelian randomization using the MR Egger, weighted median, inverse variance weighted, simple mode, and weighted mode method estimates using metabolite summary statistics from the UK Biobank as exposures and peripheral artery disease (PAD) summary statistics from Million Veterans Program (MVP) as the outcome.

Supplementary Table 7. Table of bidirectional, two-sample Mendelian randomization using the MR Egger, weighted median, inverse variance weighted, simple mode, and weighted mode method estimates using metabolite summary statistics from the UK Biobank as outcomes and peripheral artery disease (PAD) summary statistics from Million Veterans Program (MVP) as the exposure.

Supplementary Table 8. Table of bidirectional, two-sample Mendelian randomization using the MR Egger, weighted median, inverse variance weighted, simple mode, and weighted mode method estimates using metabolite summary statistics from the UK

Biobank as exposures and venous thromboembolism (VTE) summary statistics from Million Veterans Program (MVP) as the outcome.

Supplementary Table 9. Table of bidirectional, two-sample Mendelian randomization using the MR Egger, weighted median, inverse variance weighted, simple mode, and weighted mode method estimates using metabolite summary statistics from the UK Biobank as outcomes and venous thromboembolism (VTE) summary statistics from Million Veterans Program (MVP) as the exposure.

Supplementary Table 10. Table of sensitivity analysis results assessing heterogeneity for two-sample Mendelian randomization using metabolites summary statistics from the UK Biobank as exposures and coronary artery disease (CAD), peripheral artery disease (PAD), and venous thromboembolism (VTE) summary statistics from CARDIoGRAMplusC4D 2015 and Million Veterans Program (MVP) as outcomes.

Supplementary Table 11. Table of sensitivity analysis results assessing horizontal pleiotropy for two-sample Mendelian randomization using metabolites summary statistics from the UK Biobank as exposures and coronary artery disease (CAD), peripheral artery disease (PAD), and venous thromboembolism (VTE) summary statistics from CARDIoGRAMplusC4D 2015 and Million Veterans Program (MVP) as outcomes.

Supplementary Table 12. Table of multivariable Mendelian randomization using 87 sets of metabolite summary statistics from the UK Biobank as exposures and coronary artery disease (CAD) summary statistics from CARDIoGRAMplusC4D 2015 as the outcome. Metabolite sets were determined by selecting the metabolites with significant causal effects on CAD in univariable Mendelian randomization such that genetic instruments included pool of all genetic variants associated with the 87 metabolites.

Supplementary Table 13. Table of multivariable Mendelian randomization using 36 sets of metabolite summary statistics from the UK Biobank as exposures and peripheral artery disease (PAD) summary statistics from Million Veterans Program (MVP) as the outcome. Metabolite sets were determined by selecting the metabolites with significant causal effects on PAD in univariable Mendelian randomization such that genetic instruments included pool of all genetic variants associated with the 36 metabolites.

Supplementary Table 14. Table of multivariable Mendelian randomization using 2 sets of metabolite summary statistics from the UK Biobank as exposures and venous thromboembolism (VTE) summary statistics from Million Veterans Program (MVP) as the outcome. Metabolite sets were determined by selecting the metabolites with significant

causal effects on VTE in univariable Mendelian randomization such that genetic instruments included pool of all genetic variants associated with the 2 metabolites.

References

1. Mensah GA, Roth GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. *J Am Coll Cardiol*. Nov 19 2019;74(20):2529-2532. doi:10.1016/j.jacc.2019.10.009
2. Klarin D, Lynch J, Aragam K, et al. Genome-wide association study of peripheral artery disease in the Million Veteran Program. *Nat Med*. Aug 2019;25(8):1274-1279. doi:10.1038/s41591-019-0492-5
3. Levin MG, Zuber V, Walker VM, et al. Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease. *Circulation*. Aug 03 2021;144(5):353-364. doi:10.1161/CIRCULATIONAHA.121.053797
4. Identification of genetic correlates of coronary artery disease in diverse ancestral populations. *Nat Med*. Aug 2022;28(8):1548-1549. doi:10.1038/s41591-022-01915-y
5. Aragam KG, Jiang T, Goel A, et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. *Nat Genet*. Dec 2022;54(12):1803-1815. doi:10.1038/s41588-022-01233-6
6. Klarin D, Busenkell E, Judy R, et al. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. *Nat Genet*. Nov 2019;51(11):1574-1579. doi:10.1038/s41588-019-0519-3
7. Poredos P, Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. *Angiology*. 2007;58(3):309-15. doi:10.1177/0003319707302494
8. Iliou A, Mikros E, Karaman I, et al. Metabolic phenotyping and cardiovascular disease: an overview of evidence from epidemiological settings. *Heart*. Jul 2021;107(14):1123-1129. doi:10.1136/heartjnl-2019-315615
9. Julkunen H, Cichońska A, Tiainen M, et al. Atlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank. *Nat Commun*. Feb 03 2023;14(1):604. doi:10.1038/s41467-023-36231-7
10. Yu Z, Zekavat SM, Haidermota S, et al. Genome-wide pleiotropy analysis of coronary artery disease and pneumonia identifies shared immune pathways. *Sci Adv*. Apr 22 2022;8(16):eabl4602. doi:10.1126/sciadv.abl4602
11. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol*. Feb 2003;32(1):1-22. doi:10.1093/ije/dyg070
12. Fang S, Holmes MV, Gaunt TR, Davey Smith G, Richardson TG. Constructing an atlas of associations between polygenic scores from across the human phenome and circulating metabolic biomarkers. *Elife*. Oct 11 2022;11doi:10.7554/eLife.73951
13. Julkunen H, Cichońska A, Slagboom PE, Würtz P, Initiative NHUB. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. *Elife*. May 04 2021;10doi:10.7554/eLife.63033
14. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLoS medicine*. Mar 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779
15. Nikpay M, Goel A, Won HH, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet*. Oct 2015;47(10):1121-1130. doi:10.1038/ng.3396

16. Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across human diseases and traits. *Nat Genet.* Nov 2015;47(11):1236-41. doi:10.1038/ng.3406
17. Scheinin I, Kalimeri M, Jagerroos V, et al. NMR Data Analysis Tutorial. 2020.
18. Hartwig FP, Davies NM, Hemani G, Davey Smith G. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. *Int J Epidemiol.* 12 01 2016;45(6):1717-1726. doi:10.1093/ije/dyx028
19. Borges MC, Haycock PC, Zheng J, et al. Role of circulating polyunsaturated fatty acids on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid genetic association data from over 114,000 UK Biobank participants. *BMC Med.* Jun 13 2022;20(1):210. doi:10.1186/s12916-022-02399-w
20. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife.* 05 30 2018;7doi:10.7554/eLife.34408
21. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLoS Genet.* Nov 2017;13(11):e1007081. doi:10.1371/journal.pgen.1007081
22. Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing Mendelian randomization investigations. *Wellcome Open Res.* 2019;4:186. doi:10.12688/wellcomeopenres.15555.2
23. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol.* Nov 2013;37(7):658-65. doi:10.1002/gepi.21758
24. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. *Epidemiology.* Jan 2017;28(1):30-42. doi:10.1097/EDE.0000000000000559
25. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. *Am J Epidemiol.* Feb 15 2015;181(4):251-60. doi:10.1093/aje/kwu283
26. Jia A, Zeng W, Yu L, Zeng H, Lu Z, Song Y. Very low-density lipoprotein cholesterol is associated with extent and severity of coronary artery disease in patients with type 2 diabetes mellitus. *SAGE Open Med.* 2019;7:2050312119871786. doi:10.1177/2050312119871786
27. Aday AW, Everett BM. Dyslipidemia Profiles in Patients with Peripheral Artery Disease. *Curr Cardiol Rep.* Apr 22 2019;21(6):42. doi:10.1007/s11886-019-1129-5
28. National Cholesterol Education Program (NCEP) Expert Panel on Detection Ea, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* Dec 17 2002;106(25):3143-421.
29. Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. *Circ Res.* Feb 19 2016;118(4):547-63. doi:10.1161/CIRCRESAHA.115.306249
30. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. *Curr Cardiol Rep.* Dec 2011;13(6):544-52. doi:10.1007/s11886-011-0220-3

31. Franczyk B, Gluba-Brzózka A, Ławiński J, Rysz-Górczyńska M, Rysz J. Metabolomic Profile in Venous Thromboembolism (VTE). *Metabolites*. Jul 29 2021;11(8)doi:10.3390/metabo11080495
32. Lin L, Luo P, Yang M, Wang J, Hou W, Xu P. A bidirectional Mendelian randomized study of classical blood lipids and venous thrombosis. *Sci Rep*. Mar 08 2023;13(1):3904. doi:10.1038/s41598-023-31067-z
33. Tomas L, Edsfeldt A, Mollet IG, et al. Altered metabolism distinguishes high-risk from stable carotid atherosclerotic plaques. *Eur Heart J*. Jun 21 2018;39(24):2301-2310. doi:10.1093/eurheartj/ehy124